Troglitazone

Drug #1534

An oral hypoglycemic used for the treatment of type-II diabetes mellitus. Troglitazone has been associated with severe hepatic reactions, which has led to the withdrawal of this drug in the UK.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin.

Molecular Weight: 441.5 · pK_a: 6.1, 12 · Solubility in Water: 1 in 7500000 · Solubility in Alcohol: 1 in 135 · Non-proprietary name: Troglitazone.

Pharmacokinetics

Absorption: Troglitazone has an oral bioavailability is 26.5% (±26.5%).

Distribution: Troglitazone has a volume of distribution is 300 litre. plasma protein binding is > 99 %.

Elimination: plasma half-life is 10 - 15 hr.

Indications

Troglitazone is primarily indicated in conditions like Diabetes insipidus.

Contraindications

Troglitazone is contraindicated in conditions like Diabetes mellitus, Hypersensitivity, Pregnancy.

Dosage

None recorded.

Drug Interactions

Unknown2 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Troglitazone is known to cause more or less tolerable side effects which are usually transient. These include Diarrhea, Fatigue, Headache, Malaise, Musculoskeletal pain , Nausea, Vomiting .

Warnings / Precautions

It should be used with caution in patients with heart failure. Regular monitoring of liver function during therapy and withdrawal of drug in any patient who develops jaundice or sign of liver dysfunction is required.

Available Brands

None recorded.

Storage Conditions

Troglitazone should be stored Tab.

Drug Classification

1.18.7.2 — Oral hypoglycemics